MX375030B - Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cancer. - Google Patents
Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cancer.Info
- Publication number
- MX375030B MX375030B MX2016000336A MX2016000336A MX375030B MX 375030 B MX375030 B MX 375030B MX 2016000336 A MX2016000336 A MX 2016000336A MX 2016000336 A MX2016000336 A MX 2016000336A MX 375030 B MX375030 B MX 375030B
- Authority
- MX
- Mexico
- Prior art keywords
- heteroaryl
- aryl
- cancer
- triazine
- bis
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 title 1
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 abstract 1
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361845352P | 2013-07-11 | 2013-07-11 | |
| PCT/US2014/046204 WO2015006592A1 (en) | 2013-07-11 | 2014-07-10 | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016000336A MX2016000336A (es) | 2016-08-08 |
| MX375030B true MX375030B (es) | 2025-03-06 |
Family
ID=51261261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016000336A MX375030B (es) | 2013-07-11 | 2014-07-10 | Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cancer. |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9724350B2 (OSRAM) |
| EP (1) | EP3019490B1 (OSRAM) |
| JP (1) | JP6471155B2 (OSRAM) |
| KR (1) | KR102302091B1 (OSRAM) |
| CN (1) | CN105492435B (OSRAM) |
| AU (1) | AU2014287122B9 (OSRAM) |
| BR (1) | BR112016000489A8 (OSRAM) |
| CA (1) | CA2917592A1 (OSRAM) |
| CL (1) | CL2016000045A1 (OSRAM) |
| CR (1) | CR20160022A (OSRAM) |
| EA (1) | EA032070B1 (OSRAM) |
| ES (1) | ES2807582T3 (OSRAM) |
| IL (1) | IL243522B (OSRAM) |
| MX (1) | MX375030B (OSRAM) |
| MY (1) | MY185687A (OSRAM) |
| NI (1) | NI201600007A (OSRAM) |
| NZ (1) | NZ715738A (OSRAM) |
| PE (1) | PE20160744A1 (OSRAM) |
| PH (1) | PH12016500055B1 (OSRAM) |
| SA (1) | SA516370386B1 (OSRAM) |
| SG (1) | SG11201600058XA (OSRAM) |
| UA (1) | UA119242C2 (OSRAM) |
| WO (1) | WO2015006592A1 (OSRAM) |
| ZA (1) | ZA201600210B (OSRAM) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| CA2917671A1 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | 2,4-or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer |
| WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| EP3019490B1 (en) * | 2013-07-11 | 2020-06-03 | Agios Pharmaceuticals, Inc. | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| EA030428B1 (ru) | 2013-08-02 | 2018-08-31 | Аджиос Фармасьютикалз, Инк. | Терапевтически активные соединения и способы их применения |
| US9694013B2 (en) | 2014-09-29 | 2017-07-04 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CN107531675A (zh) | 2015-02-04 | 2018-01-02 | 安吉奥斯医药品有限公司 | 治疗活性化合物及其使用方法 |
| EP3331866B1 (en) | 2015-08-05 | 2023-07-26 | Les Laboratoires Servier | Methods of preparing a 6-heteroaryl-1,3,5-triazine-2,4-diol and a 6-heteroaryl-1,3,5-triazine-2,4-diamine |
| EP3362057A1 (en) | 2015-10-15 | 2018-08-22 | Agios Pharmaceuticals, Inc. | Combination therapy for treating malignancies |
| EP3362070B1 (en) * | 2015-10-15 | 2021-01-27 | Celgene Corporation | Combination of a mutant isocitrate dehydrogenase 2 inhibitor with azacitidine and its use for treating acute myelogenous leukemia |
| EP3383400B1 (en) | 2015-12-04 | 2022-01-05 | Les Laboratoires Servier | Methods of treatment of malignancies |
| WO2017140758A1 (en) | 2016-02-19 | 2017-08-24 | Debiopharm International S.A. | Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers |
| MX390396B (es) | 2016-02-26 | 2025-03-20 | Celgene Corp | Enasidenib para usarse en leucemia mieloide aguda recidivante o refractaria. |
| CN107382840B (zh) * | 2016-05-16 | 2020-09-01 | 四川大学 | 吡啶类化合物及其作为idh功能变异突变体抑制剂类药物的用途 |
| CN107556366B (zh) * | 2016-06-30 | 2025-02-07 | 上海海和药物研究开发股份有限公司 | 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途 |
| KR102232614B1 (ko) * | 2016-07-21 | 2021-03-29 | 난징 산홈 팔마세우티칼 컴퍼니 리미티드 | 이소시트레이트 탈수소효소 억제제의 화학적 화합물 및 이의 적용 |
| US20180042930A1 (en) | 2016-08-03 | 2018-02-15 | Celgene Corporation | Methods of treatment of malignancies |
| BR112019004356A2 (pt) | 2016-09-07 | 2019-05-28 | Celgene Corporation | composições de comprimido |
| EP3618828B1 (en) | 2017-05-05 | 2023-11-01 | Memorial Sloan Kettering Cancer Center | Methods of treatment of myeloproliferative neoplasm |
| PL3644999T3 (pl) | 2017-06-30 | 2023-05-08 | Celgene Corporation | Kompozycje i sposoby zastosowania 2-(4-chlorofenylo)-n-((2-(2,6-dioksopiperydyn-3-ylo)-1-oksoizoindolin-5-ylo)metylo)-2,2-difluoroacetamidu |
| CN109467538A (zh) * | 2017-09-07 | 2019-03-15 | 和记黄埔医药（上海）有限公司 | 环烯烃取代的杂芳环类化合物及其用途 |
| CN110054617A (zh) * | 2018-01-19 | 2019-07-26 | 南京圣和药业股份有限公司 | 三嗪类化合物、其制备方法及用途 |
| US12215094B2 (en) | 2018-11-02 | 2025-02-04 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| CN111662242B (zh) * | 2019-03-08 | 2023-10-24 | 中国药科大学 | 杂环类idh突变体抑制剂、其制备方法及用途 |
| CN111087408B (zh) * | 2020-01-03 | 2021-04-02 | 浙江大学 | 一种大环结构的idh2突变体抑制剂及其医药用途 |
| CN112250639B (zh) * | 2020-11-19 | 2022-05-24 | 浙江工业大学 | 一种杂环取代的芳胺类化合物及其制备方法和应用 |
| CN112592958B (zh) * | 2020-12-07 | 2022-11-01 | 山东大学第二医院 | 利用fad依赖型d-2-羟基戊二酸脱氢酶和刃天青检测d-2-羟基戊二酸的方法 |
| CN112645893A (zh) * | 2020-12-28 | 2021-04-13 | 营口昌成新材料科技有限公司 | 一种二卤代均三嗪的合成方法 |
| CN115536637B (zh) * | 2022-10-24 | 2025-03-18 | 陕西中医药大学 | 一种均三嗪类衍生物及其合成方法与用途 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2390529A (en) * | 1942-02-03 | 1945-12-11 | Ernst A H Friedheim | Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds |
| BE754242A (fr) | 1970-07-15 | 1971-02-01 | Geigy Ag J R | Diamino-s-triazines et dinitro-s-triazines |
| US3867383A (en) | 1971-03-29 | 1975-02-18 | Ciba Geigy Corp | Monoanthranilatoanilino-s-triazines |
| JPS5011392B2 (OSRAM) * | 1971-08-07 | 1975-04-30 | ||
| CH606334A5 (OSRAM) | 1974-06-21 | 1978-10-31 | Ciba Geigy Ag | |
| JPS58186682A (ja) * | 1982-04-27 | 1983-10-31 | 日本化薬株式会社 | セルロ−ス又はセルロ−ス含有繊維材料の染色法 |
| DE3512630A1 (de) * | 1985-04-06 | 1986-10-23 | Hoechst Ag, 6230 Frankfurt | Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern |
| WO1993017009A1 (fr) | 1992-02-28 | 1993-09-02 | Zenyaku Kogyo Kabushiki Kaisha | DERIVE DE s-TRIAZINE ET REMEDE CONTRE DES MALADIES DEPENDENTES DE L'×STROGENE LE CONTENANT COMME INGREDIENT ACTIF |
| GB9602166D0 (en) | 1996-02-02 | 1996-04-03 | Zeneca Ltd | Aminoheterocyclic derivatives |
| EP0945446A4 (en) | 1996-11-14 | 1999-12-08 | Nissan Chemical Ind Ltd | CYANOETHYLMELAMINE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME |
| JPH11158073A (ja) | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | アデノシンａ３拮抗剤 |
| US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| UY25842A1 (es) | 1998-12-16 | 2001-04-30 | Smithkline Beecham Corp | Antagonistas de receptores de il-8 |
| US6274620B1 (en) * | 1999-06-07 | 2001-08-14 | Biochem Pharma Inc. | Thiophene integrin inhibitors |
| HUP0402352A2 (hu) | 2001-06-19 | 2005-02-28 | Bristol-Myers Squibb Co. | Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények |
| JP4344241B2 (ja) | 2001-08-17 | 2009-10-14 | チバ ホールディング インコーポレーテッド | トリアジン誘導体、およびサンスクリーンとしてのその使用 |
| JP4753336B2 (ja) | 2001-09-04 | 2011-08-24 | 日本化薬株式会社 | 新規アリル化合物及びその製法 |
| US7291616B2 (en) * | 2001-10-31 | 2007-11-06 | Cell Therapeutics, Inc. | Aryl triazines as LPAAT-β inhibitors and uses thereof |
| US6878196B2 (en) | 2002-01-15 | 2005-04-12 | Fuji Photo Film Co., Ltd. | Ink, ink jet recording method and azo compound |
| SI2256108T1 (sl) | 2002-07-18 | 2016-05-31 | Janssen Pharmaceutica N.V. | Substituirani triazinski kinazni inhibitorji |
| JP2004107220A (ja) | 2002-09-13 | 2004-04-08 | Mitsubishi Pharma Corp | ＴＮＦ−α産生抑制剤 |
| CL2003002353A1 (es) | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
| EP1575580A4 (en) | 2002-12-02 | 2009-06-10 | Arqule Inc | METHOD FOR TREATING CARCINOMA |
| US7282568B2 (en) | 2002-12-16 | 2007-10-16 | Medarex, Inc. | Human monoclonal antibodies against interleukin 8 (IL-8) |
| WO2005035507A2 (en) | 2003-10-10 | 2005-04-21 | Bayer Pharmaceuticals Corporation | 4-aminopyrimidine derivatives for treatment of hyperproliferative disorders |
| WO2005060956A1 (en) | 2003-12-12 | 2005-07-07 | University Of Maryland, Baltimore | IMMUNOMODULATORY COMPOUNDS THAT TARGET AND INHIBIT THE pY+3 BINDING SITE OF TYROSENE KINASE p56 LCK SH2 DOMAIN |
| US20050245508A1 (en) | 2003-12-24 | 2005-11-03 | Scios, Inc. | Treatment of malignant gliomas with TGF-beta inhibitors |
| US7622486B2 (en) | 2004-09-23 | 2009-11-24 | Reddy Us Therapeutics, Inc. | Pyridine compounds, process for their preparation and compositions containing them |
| BRPI0606930A2 (pt) | 2005-01-25 | 2009-12-01 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, métodos para a produção de um efeito de inibição de b-raf em um animal de sangue quente, para a produção de um efeito anti-cáncer em um animal de sangue quente e para o tratamento de doenças de um animal em um animal de sangue quente |
| US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| TW200815426A (en) | 2006-06-28 | 2008-04-01 | Astrazeneca Ab | New pyridine analogues II 333 |
| US20100234341A1 (en) | 2006-12-04 | 2010-09-16 | Marion Lanier | Substituted pyrimidines as adenosine receptor antagonists |
| EP2120964A2 (en) | 2006-12-15 | 2009-11-25 | Abraxis BioScience, Inc. | Triazine derivatives and their therapeutical applications |
| DK2152676T3 (da) | 2007-04-30 | 2013-07-01 | Prometic Biosciences Inc | Triazinderivater, sammensætninger, der indeholder sådanne derivater, og fremgangsmåde til behandling af cancer og autoimmunsygdomme ved anvendelse af sådanne derivater |
| CA2683152A1 (en) | 2007-06-11 | 2008-12-18 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
| KR20100064381A (ko) | 2007-10-10 | 2010-06-14 | 다케다 야쿠힌 고교 가부시키가이샤 | 아미드 화합물 |
| US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| GB0805477D0 (en) * | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
| JP5277685B2 (ja) | 2008-03-26 | 2013-08-28 | 富士ゼロックス株式会社 | 電子写真感光体、画像形成装置、プロセスカートリッジ及び画像形成方法 |
| CN101575408B (zh) | 2008-05-09 | 2013-10-30 | Mca技术有限公司 | 用作阻燃剂和光稳定剂的聚三嗪基化合物 |
| WO2010028179A1 (en) | 2008-09-03 | 2010-03-11 | Dr. Reddy's Laboratories Ltd. | Heterocyclic compounds as gata modulators |
| JP2010079130A (ja) | 2008-09-29 | 2010-04-08 | Fuji Xerox Co Ltd | 電子写真感光体、プロセスカートリッジ、及び画像形成装置 |
| JP2010181540A (ja) | 2009-02-04 | 2010-08-19 | Fuji Xerox Co Ltd | 電子写真感光体、プロセスカートリッジ、及び画像形成装置 |
| ES2453474T3 (es) | 2009-02-06 | 2014-04-07 | Nippon Shinyaku Co., Ltd. | Derivados de aminopirazina y medicamento correspondiente |
| AU2010223919B2 (en) | 2009-03-13 | 2016-03-31 | Les Laboratoires Servier | Methods and compositions for cell-proliferation-related disorders |
| CN102573485B (zh) | 2009-06-08 | 2014-11-26 | 加利福尼亚资本权益有限责任公司 | 三嗪衍生物及其治疗应用 |
| BRPI1011527A2 (pt) * | 2009-06-09 | 2016-07-26 | California Capital Equity Llc | derivados de triazina substituídos com ureidofenil e suas aplicações terapêuticas. |
| EP2440054A4 (en) | 2009-06-09 | 2012-12-12 | California Capital Equity Llc | PYRIDILTRIA INHIBITOR OF HEDGEHOG SIGNALING |
| US20120197411A1 (en) | 2009-07-10 | 2012-08-02 | Milux Holding Sa | Knee joint device and method |
| JP5473851B2 (ja) | 2009-09-30 | 2014-04-16 | 富士フイルム株式会社 | 高分子フィルム、位相差フィルム、偏光板及び液晶表示装置 |
| EP3064595B1 (en) | 2009-10-21 | 2019-02-27 | Agios Pharmaceuticals, Inc. | Methods for cell-proliferation-related disorders |
| CA2793836C (en) | 2009-10-21 | 2020-03-24 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| WO2011072174A1 (en) | 2009-12-09 | 2011-06-16 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation |
| WO2011123618A1 (en) | 2010-04-01 | 2011-10-06 | Agios Pharmaceuticals, Inc. | Methods of identifying a candidate compound |
| CN103097340B (zh) | 2010-07-16 | 2018-03-16 | 安吉奥斯医药品有限公司 | 治疗活性组合物及其使用方法 |
| SG190921A1 (en) | 2010-11-29 | 2013-07-31 | Galleon Pharmaceuticals Inc | Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases |
| EP2691391A4 (en) | 2011-03-29 | 2014-09-10 | Broad Inst Inc | COMPOUNDS AND METHODS OF TREATING DISORDERS MEDIATED BY ISOCITRATE DEHYDROGENASE |
| CN102250065B (zh) * | 2011-05-20 | 2015-05-13 | 浙江海正药业股份有限公司 | 取代的三嗪苯脲衍生物及其用途 |
| TWI555737B (zh) | 2011-05-24 | 2016-11-01 | 拜耳知識產權公司 | 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺 |
| CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN102659765B (zh) | 2011-12-31 | 2014-09-10 | 沈阳药科大学 | 嘧啶及三嗪类化合物的制备方法和应用 |
| AU2013207289B2 (en) * | 2012-01-06 | 2017-09-21 | Les Laboratoires Servier | Therapeutically active compounds and their methods of use |
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| WO2013107405A1 (en) | 2012-01-19 | 2013-07-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2013133367A1 (ja) * | 2012-03-09 | 2013-09-12 | カルナバイオサイエンス株式会社 | 新規トリアジン誘導体 |
| EP3019490B1 (en) * | 2013-07-11 | 2020-06-03 | Agios Pharmaceuticals, Inc. | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
| US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
-
2014
- 2014-07-10 EP EP14745309.6A patent/EP3019490B1/en active Active
- 2014-07-10 WO PCT/US2014/046204 patent/WO2015006592A1/en not_active Ceased
- 2014-07-10 SG SG11201600058XA patent/SG11201600058XA/en unknown
- 2014-07-10 AU AU2014287122A patent/AU2014287122B9/en active Active
- 2014-07-10 PE PE2016000042A patent/PE20160744A1/es unknown
- 2014-07-10 JP JP2016525491A patent/JP6471155B2/ja active Active
- 2014-07-10 MX MX2016000336A patent/MX375030B/es active IP Right Grant
- 2014-07-10 US US14/904,032 patent/US9724350B2/en active Active
- 2014-07-10 MY MYPI2016700044A patent/MY185687A/en unknown
- 2014-07-10 NZ NZ715738A patent/NZ715738A/en unknown
- 2014-07-10 KR KR1020167003352A patent/KR102302091B1/ko active Active
- 2014-07-10 CN CN201480047026.XA patent/CN105492435B/zh active Active
- 2014-07-10 EA EA201690204A patent/EA032070B1/ru not_active IP Right Cessation
- 2014-07-10 ES ES14745309T patent/ES2807582T3/es active Active
- 2014-07-10 BR BR112016000489A patent/BR112016000489A8/pt not_active Application Discontinuation
- 2014-07-10 CA CA2917592A patent/CA2917592A1/en not_active Abandoned
- 2014-10-07 UA UAA201601118A patent/UA119242C2/uk unknown
-
2016
- 2016-01-07 IL IL243522A patent/IL243522B/en active IP Right Grant
- 2016-01-07 PH PH12016500055A patent/PH12016500055B1/en unknown
- 2016-01-08 NI NI201600007A patent/NI201600007A/es unknown
- 2016-01-11 SA SA516370386A patent/SA516370386B1/ar unknown
- 2016-01-11 CL CL2016000045A patent/CL2016000045A1/es unknown
- 2016-01-11 CR CR20160022A patent/CR20160022A/es unknown
- 2016-01-11 ZA ZA2016/00210A patent/ZA201600210B/en unknown
-
2017
- 2017-06-22 US US15/630,886 patent/US10111878B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX375030B (es) | Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cancer. | |
| EA201591612A1 (ru) | ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ | |
| CY1122805T1 (el) | Ενωσεις και μεθοδοι για την αγωγη βακτηριακων λοιμωξεων | |
| TW201613872A (en) | IRAK4 inhibiting agents | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| NI201800042A (es) | Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1 | |
| MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
| MX2020000386A (es) | Inhibidores heterociclicos de la cinasa atr. | |
| EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
| MX388321B (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| MX2018001424A (es) | Metodos para preparar 6-(aril o heteroaril)-1,3,5-triazin-2,4-diol es y 6-(aril o heteroaril)-1,3,5-triazin-2,4-diaminas. | |
| EA201790327A1 (ru) | Соединения замещенного пиперидина | |
| MX2016009663A (es) | Derivados de icariina. | |
| MX390051B (es) | Antagonistas de ep4. | |
| EA201691412A1 (ru) | Гидроксиформамидные производные и их применение | |
| MX2016010524A (es) | Derivados de piridazina para uso en la prevencion o tratamiento de trastorno ataxico. | |
| EA201491227A1 (ru) | Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2 | |
| BR112019003130A2 (pt) | agonista de ppargama para tratamento de cânceres de sangue | |
| MX2022006229A (es) | Composiciones y metodos para el tratamiento de resistencia a la insulina. | |
| BR112017009854A2 (pt) | composto, uso de um composto, e, método para tratamento de leucemia. | |
| TH171543A (th) | สารประกอบ n,6-บิส(เอริล หรือเฮเทอโรเอริล)-1,3,5-ไตรอะซีน-2,4-ไดเอมีน ดังที่เป็นตัวยับยั้งการ กลายพันธุ์ idh2 สำหรับการรักษามะเร็ง | |
| TH1601000068A (th) | สารประกอบ n,6-บิส(เอริล หรือเฮเทอโรเอริล)-1,3,5-ไตรอะซีน-2,4-ไดเอมีน ดังที่เป็นตัวยับยั้งการ กลายพันธุ์ idh2 สำหรับการรักษามะเร็ง | |
| EA202090336A1 (ru) | Соединения, их соли и способы лечения заболеваний | |
| BR112017004947A2 (pt) | composto ou sal farmaceuticamente aceitável, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento de mieloma múltiplo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |